Several studies have characterized the cellular and molecular mechanisms of hepatocyte
injury caused by the retention of hydrophobic bile acids (BAs) in cholestatic diseases. BAs …

Molecular medicine has led to rapid advances in the characterization of hepatobiliary
transport systems that determine the uptake and excretion of bile salts and other biliary …

Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver
diseases. Experimental evidence suggests three major mechanisms of action:(1) protection …

Cholangiocytes are epithelial cells that line the intra-and extrahepatic ducts of the biliary
tree. The main physiologic function of cholangiocytes is modification of hepatocyte-derived …

Ursodeoxycholic acid (UDCA) exerts anticholestatic effects in various cholestatic disorders.
Several potential mechanisms and sites of action of UDCA have been unraveled in clinical …

Ursodeoxycholic acid (UDCA) is widely used for the treatment of a variety of chronic
cholestatic liver diseases. At present, it is the only drug approved by the United States Food …

Primary biliary cirrhosis (PBC) is a chronic inflammatory autoimmune disease that mainly
targets the cholangiocytes of the interlobular bile ducts in the liver. The condition primarily …

The farnesoid X receptor (FXR) controls the synthesis and transport of bile acids (BAs). Mice
lacking expression of FXR, designated Fxr-null, have elevated levels of serum and hepatic …

UDCA (ursodeoxycholic acid) is the therapeutic agent most widely used for the treatment of
cholestatic hepatopathies. Its use has expanded to other kinds of hepatic diseases, and …

Background & Aims: The effects of ursodeoxycholic acid (UDCA) in biliary obstruction are
unclear. We aimed to determine the effects of UDCA in bile duct–ligated and in Mdr2 …